Hospital
Freeman-Oak Hill Health System
Freeman-Oak Hill Health System was paid $33.16M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 34% of everything it billed.
33Billing provider infoFREEMAN-OAK HILL HEALTH SYSTEM
JOPLIN, MO 64804
JOPLIN, MO 64804
33aNPI1265546048assigned 08/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.16M
24GClaims529,336
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#11 of 74
Median peer was paid$4.44M
This provider vs. median7.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,823 | $6.33M | |
| 2019 | 60,424 | $5.31M | |
| 2020 | 56,119 | $3.87M | |
| 2021 | 56,471 | $1.97M | |
| 2022 | 81,331 | $4.11M | |
| 2023 | 115,799 | $6.68M | |
| 2024incomplete | 78,369 | $4.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 34% | 191,945 | 171,072 | $11.31M |
| X4011 | State-specific procedure code | 15% | 13,285 | 12,587 | $4.90M |
| X4003 | 11% | 65,379 | 57,910 | $3.53M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 5,110 | 4,861 | $1.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.4% | 8,103 | 7,850 | $1.45M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.6% | 37,483 | 33,610 | $1.20M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 12,018 | 11,008 | $637K |
| 80053 | Comprehensive metabolic panel | 1.9% | 29,593 | 26,277 | $632K |
| X4006 | 1.7% | 591 | 447 | $552K | |
| Y7506 | 1.5% | 3,266 | 1,590 | $505K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 5,392 | 4,730 | $498K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 3,110 | 1,774 | $465K |
196 more codes
| 81001 | 1.3% | 11,506 | $421K | |
| 99283 | Emergency room visit (moderate) | 1.1% | 2,720 | $354K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 6,347 | $333K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,220 | $317K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,817 | $274K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,547 | $245K |
| J3490 | Unclassified drugs | <1% | 8,497 | $214K |
| 80306 | <1% | 6,468 | $210K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,816 | $179K |
| 76820 | <1% | 2,395 | $161K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,222 | $156K |
| G0378 | Hospital observation service, per hour | <1% | 757 | $127K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,470 | $125K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 147 | $121K |
| 90999 | Dialysis (unlisted procedure) | <1% | 3,667 | $121K |
| 81002 | <1% | 10,626 | $102K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,939 | $100K |
| 20610 | <1% | 837 | $97K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,590 | $96K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 153 | $89K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 286 | $83K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,651 | $83K |
| 95811 | <1% | 170 | $81K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 639 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,203 | $74K |
| Y7507 | <1% | 739 | $73K | |
| 94726 | <1% | 768 | $73K | |
| 62323 | <1% | 395 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,464 | $64K |
| Q3014 | Telehealth originating site facility fee | <1% | 3,297 | $60K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,428 | $57K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 872 | $55K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 679 | $53K |
| 77336 | <1% | 961 | $50K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,666 | $46K |
| 77334 | <1% | 281 | $39K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 902 | $38K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 837 | $38K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,383 | $38K |
| 29581 | <1% | 528 | $37K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 763 | $33K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 586 | $29K |
| 87400 | <1% | 207 | $27K | |
| 73030 | <1% | 1,058 | $26K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 155 | $26K |
| 86803 | <1% | 534 | $26K | |
| 86063 | <1% | 380 | $25K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 89 | $23K |
| 83655 | <1% | 1,093 | $23K | |
| 73100 | <1% | 437 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,440 | $21K |
| 80061 | Lipid panel | <1% | 1,661 | $19K |
| 84484 | <1% | 2,069 | $18K | |
| 77386 | <1% | 115 | $18K | |
| 88300 | <1% | 674 | $18K | |
| 77300 | <1% | 150 | $17K | |
| 94729 | <1% | 620 | $16K | |
| 82550 | <1% | 2,240 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 647 | $15K |
| 87653 | <1% | 430 | $14K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 53 | $13K |
| 85018 | <1% | 1,199 | $13K | |
| 84439 | <1% | 1,239 | $13K | |
| 77290 | <1% | 92 | $12K | |
| 64493 | <1% | 38 | $12K | |
| 82553 | <1% | 1,480 | $12K | |
| 83690 | <1% | 1,003 | $12K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 183 | $12K |
| 87807 | <1% | 477 | $12K | |
| 94060 | <1% | 104 | $11K | |
| 88304 | <1% | 246 | $11K | |
| 84703 | <1% | 802 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 92 | $10K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 170 | $10K |
| 84436 | <1% | 193 | $9K | |
| 84479 | <1% | 194 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 599 | $9K |
| 31575 | <1% | 135 | $9K | |
| 87428 | <1% | 439 | $9K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 55 | $9K |
| 94681 | <1% | 66 | $8K | |
| 77295 | <1% | 26 | $8K | |
| 17110 | <1% | 77 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 246 | $7K |
| 77470 | <1% | 38 | $7K | |
| 73564 | <1% | 128 | $7K | |
| 84481 | <1% | 100 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 111 | $6K |
| 84482 | <1% | 43 | $6K | |
| 71250 | <1% | 104 | $5K | |
| 94750 | <1% | 135 | $5K | |
| 29075 | <1% | 52 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 55 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 53 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 126 | $5K |
| 93296 | <1% | 422 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 29 | $5K |
| 64615 | <1% | 55 | $4K | |
| 80081 | <1% | 71 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 68 | $4K |
| 85027 | <1% | 151 | $4K | |
| 94200 | <1% | 134 | $4K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 515 | $4K |
| 69210 | <1% | 183 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 723 | $4K |
| 85007 | <1% | 129 | $4K | |
| 80055 | <1% | 39 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 235 | $3K |
| 81000 | <1% | 499 | $3K | |
| 83735 | <1% | 744 | $3K | |
| 73502 | <1% | 77 | $3K | |
| 11102 | <1% | 26 | $3K | |
| 82950 | <1% | 161 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 30 | $2K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 72 | $2K |
| 95117 | <1% | 519 | $2K | |
| 77338 | <1% | 12 | $2K | |
| 90686 | <1% | 456 | $2K | |
| 82784 | <1% | 353 | $2K | |
| 84145 | <1% | 87 | $2K | |
| 82947 | <1% | 330 | $2K | |
| 81025 | <1% | 400 | $2K | |
| 87071 | <1% | 41 | $2K | |
| 87040 | <1% | 113 | $2K | |
| 83605 | <1% | 163 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 24 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 539 | $1K |
| 87150 | <1% | 141 | $1K | |
| 73560 | <1% | 30 | $1K | |
| 17000 | <1% | 26 | $1K | |
| 86364 | <1% | 165 | $1K | |
| 92511 | <1% | 12 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 253 | $1K |
| 82248 | <1% | 345 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 15 | $991.80 |
| 92567 | <1% | 110 | $939.97 | |
| 29580 | <1% | 19 | $923.28 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 13 | $920.00 |
| 83516 | <1% | 156 | $878.55 | |
| 92557 | <1% | 42 | $878.14 | |
| 85730 | <1% | 253 | $869.05 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 13 | $859.56 |
| 77280 | <1% | 14 | $839.97 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 129 | $821.52 |
| 17250 | <1% | 14 | $818.06 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 407 | $815.09 |
| 87070 | <1% | 146 | $789.13 | |
| J2704 | Injection, propofol, 10 mg | <1% | 198 | $787.01 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 16 | $735.64 |
| 80069 | <1% | 115 | $710.21 | |
| 73610 | <1% | 17 | $702.13 | |
| 82803 | <1% | 32 | $688.71 | |
| 85610 | <1% | 286 | $666.19 | |
| 94010 | <1% | 12 | $644.61 | |
| 74018 | <1% | 28 | $620.19 | |
| 73070 | <1% | 14 | $610.42 | |
| 82607 | <1% | 52 | $513.12 | |
| 87077 | <1% | 71 | $491.05 | |
| J1815 | Injection, insulin, per 5 units | <1% | 54 | $486.83 |
| 83970 | <1% | 30 | $469.72 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $462.73 |
| 82150 | <1% | 112 | $458.23 | |
| 87205 | <1% | 149 | $410.14 | |
| 87186 | <1% | 55 | $402.78 | |
| 80074 | <1% | 12 | $389.25 | |
| 86003 | <1% | 14 | $370.38 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13 | $350.04 |
| 95886 | <1% | 27 | $311.07 | |
| 87641 | <1% | 14 | $259.29 | |
| 87581 | <1% | 13 | $253.50 | |
| 87486 | <1% | 13 | $253.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 71 | $171.55 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 104 | $167.91 |
| 86140 | <1% | 56 | $158.29 | |
| 84146 | <1% | 41 | $145.12 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 45 | $131.71 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $126.36 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 27 | $98.75 |
| 99070 | <1% | 466 | $97.86 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 26 | $93.30 |
| 80047 | <1% | 15 | $60.50 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 28 | $51.43 |
| 87081 | <1% | 25 | $42.50 | |
| A6261 | Wound filler, gel/paste, per fluid ounce, not otherwise specified | <1% | 19 | $21.76 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 168 | $19.00 |
| 76937 | <1% | 12 | $13.74 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $11.61 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 21 | $1.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 42 | $0.32 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 40 | $0.00 |
| 64494 | 0% | 17 | $0.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 26 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 253 | $0.00 |
| 99152 | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRADDY, STEVEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Freeman-Oak Hill Health System | Joplin, MO | $6.16M |
| Freeman Neosho Hospital | Neosho, MO | $3.49M |
| Freeman Neosho Hospital | Neosho, MO | $782K |
| Freeman Surgical Center of Pittsburg, LLC | Pittsburg, KS | $261K |
| Freeman Neosho Hospital | Anderson, MO | $105K |
| Freeman-Oak Hill Health System | Joplin, MO | $19K |
| Freeman Neosho Hospital | Neosho, MO | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.